Drug Approval | April 17, 2024
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Submission based on results from pivotal phase III trial showing all primary endpoints met
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
A game changing solution for the pharmaceutical industry
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The company plans to add 1700 beds by FY27 through the organic route
New leadership team announced at NATHEALTH Annual General Meeting 2024
The average time of dilation lasts three to eight hours
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated
